Printer Friendly

CLINICAL STUDY RESULTS ON PROMISING TREATMENT FOR ALZHEIMER'S DISEASE REPORTED BY FOREST LABORATORIES

 NEW YORK, Nov. 24 ~PRNewswire~ -- Forest Laboratories, Inc. (AMEX: FRX), an international pharmaceutical manufacturer and marketer, announced today preliminary results of its clinical studies with Synapton(R), its controlled release formulation of physostigmine, being studied for the treatment of Alzheimer's Disease.
 The studies indicate that Synapton is a promising therapeutic agent for Alzheimer's Disease patients. Forest intends to seek expanded access to the drug pursuant to a Treatment IND. Synapton is a cholinesterase inhibitor which increases the availability of acetylcholine, the neurotransmitter associated with memory and related cerebral function.
 Three controlled studies of Synapton were conducted in a total of over 800 patients in the United States and the United Kingdom. Patients were initially screened to determine if they responded to the drug. Those that responded (approximately half) were further tested in two separate six week double blind placebo controlled parallel group studies, one in the United States and the other in the United Kingdom. Those patients from both countries that did not respond in the initial screening were tested in a third study using a similar six week treatment protocol. Patients in all three studies were evaluated using an objective measurement of cognitive response, the Cognitive Subscale of the Alzheimer's Disease Assessment Scale (ADAS-COG) and a clinical response, the Clinical Global Impression of Change (CGIC).
 In the United States study statistical significance was reached in both clinical endpoints. In the United Kingdom strong favorable trends were shown in both endpoints which did not reach statistical significance, possibly due to the smaller number of patients included in the United Kingdom study. The study in the initially non-responding patients confirmed their lack of response in the six week double blind phase.
 Synapton did not produce significant toxicity such as liver toxicity or neutropenia that have been seen with other cholinesterase inhibitors. There was also no indication of a rebound effect. As with other cholinesterase inhibitors, some patients experienced nausea and vomiting.
 Forest stated that it plans to initiate a study early next year evaluating the efficacy of Synapton over a longer period of time. Forest will also apply during the first quarter of next year for a Treatment IND, which it expects will be submitted by the FDA to its Peripheral and Central Nervous System Drugs Advisory Committee.
 -0- 11~24~92
 ~CONTACT: Kenneth E. Goodman, vice president-finance of Forest Laboratories, 212-421-7850~
 (FRX)


CO: Forest Laboratories, Inc. ST: New York IN: MTC SU:

TS-PS -- NY008 -- 0893 11~24~92 08:48 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 24, 1992
Words:411
Previous Article:FRONTIER TOWN EXPANDS INTO ANIMATION
Next Article:FORGET THE RECESSION, SHOPPING HELPS WITH DEPRESSION, MAGAZINE STUDY FINDS; LEAVE MOM AND HUSBAND BEHIND, SHOPPING IS MOST FUN ALONE
Topics:


Related Articles
NeoTherapeutics' Files Investigational New Drug Application with FDA For Lead Compound, AIT-082
MERZ + CO./FOREST LABS SIGN PACT FOR MEMANTINE DEVELOPMENT.
Two Studies Show Potential Effects of Investigational Alzheimer's Drug.
Forest Laboratories, Developer of Investigational Alzheimer's Therapy, Sponsors Scientific Session at 10th Annual National Alzheimer's Disease...
Data on Forest Laboratories' Investigational Alzheimer's Disease Treatment Will be Presented at 15th American Association For Geriatric Psychiatry...
Researchers Report Namenda(TM) Provides Significant Benefits as Monotherapy to Patients With Mild to Moderate Alzheimer's Disease.
Forest Announces That a Just Completed Clinical Study of Memantine For Neuropathic Pain Failed to Demonstrate a Statistically Significant Difference...
Forest Laboratories Submits New Drug Application For Investigational Alzheimer's Treatment Memantine.
Forest Laboratories Submits New Drug Application for Memantine for Treatment Of Moderate-to-Severe Alzheimer's Disease.
New Study Shows Improved Cognition Relative to Baseline for Alzheimer's Patients Treated With Investigational Memantine and Donepezil.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters